Abbas, A., Roth, B. L.: Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders. Expert Opin. Pharmacother., 9: 3251-3259, 2008.
Alex, K. D., Pehek, E. A.: Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol. Ther., 113: 296-320, 2007.
Bagdy, G., Graf, M., Anheuer, Z. E. et al.: Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635. Int. J. Neuropsychopharmacol., 4: 399-408, 2001.
Behnke, K., Søgaard, J., Martin, S. et al.: Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study. J. Clin. Psychopharmacol., 23: 358-364, 2003.
Benkert, O., Szegedi, A., Kohnen, R.: Mirtazapine compared with paroxetine in major depression. J. Clin. Psychiatry, 61: 656-663, 2000.